Relevance of Tacrolimus Trough Concentration and Hepatitis E virus Genetic Changes in Kidney Transplant Recipients With Chronic Hepatitis E.

Immunosuppressive Agents chronic hepatitis genetic diversity hepatitis E virus kidney transplantation

Journal

Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752

Informations de publication

Date de publication:
May 2024
Historique:
received: 27 07 2023
revised: 26 01 2024
accepted: 29 01 2024
medline: 6 5 2024
pubmed: 6 5 2024
entrez: 6 5 2024
Statut: epublish

Résumé

Hepatitis E virus (HEV) can cause chronic infection (≥3 months) and cirrhosis in immunocompromised patients, especially kidney transplant recipients. Low alanine aminotransferase (ALT) levels and high HEV intrahost diversity have previously been associated with evolution toward chronicity in these patients. We hypothesized that additional clinical and viral factors could be associated with the risk of chronic HEV infection. We investigated a series of 27 kidney transplant recipients with HEV infection, including 20 patients with chronic hepatitis E. High tacrolimus trough concentration at diagnosis was the most relevant marker associated with chronic hepatitis E (9.2 vs. 6.4 ng/ml, This compartmentalization highlights the diversity and complexity of HEV replication compartments. Tacrolimus trough concentration at diagnosis of HEV infection could allow an early identification of patients at high risk of chronic hepatitis E and guide treatment initiation.

Identifiants

pubmed: 38707810
doi: 10.1016/j.ekir.2024.01.054
pii: S2468-0249(24)00066-4
pmc: PMC11069011
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1333-1342

Informations de copyright

© 2024 International Society of Nephrology. Published by Elsevier Inc.

Auteurs

Nancy León-Janampa (N)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.

Natacha Boennec (N)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.

Olivier Le Tilly (O)

Service de Pharmacologie médicale, CHRU de Tours, Tours, France.

Simon Ereh (S)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.

Gabriel Herbet (G)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.

Alain Moreau (A)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.

Philippe Gatault (P)

Transplantation rénale - Immunologie clinique, CHRU de Tours, Tours, France.

Hélène Longuet (H)

Transplantation rénale - Immunologie clinique, CHRU de Tours, Tours, France.

Christelle Barbet (C)

Transplantation rénale - Immunologie clinique, CHRU de Tours, Tours, France.

Mathias Büchler (M)

Transplantation rénale - Immunologie clinique, CHRU de Tours, Tours, France.

Christophe Baron (C)

Transplantation rénale - Immunologie clinique, CHRU de Tours, Tours, France.

Catherine Gaudy-Graffin (C)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, Tours, France.

Denys Brand (D)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, Tours, France.

Julien Marlet (J)

INSERM U1259 MAVIVH, Université de Tours et CHRU de Tours, Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, Tours, France.

Classifications MeSH